Arrowhead Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Year	2023	2022	2021	2020	2019	2018 - 2004
Revenue	240.74	243.23	138.29	87.99	168.8	Upgrade
Revenue Growth (YoY)	-1.03%	75.89%	57.16%	-47.87%	945.67%	Upgrade
Gross Profit	240.74	243.23	138.29	87.99	168.8	Upgrade
Selling, General & Admin	92.55	124.43	80.98	52.28	26.56	Upgrade
Research & Development	353.19	297.31	206.34	128.88	81.05	Upgrade
Operating Expenses	445.74	421.74	287.32	181.15	107.61	Upgrade
Operating Income	-205	-178.51	-149.04	-93.16	61.19	Upgrade
Interest Expense / Income	18.33	0	0	-9.19	-6.96	Upgrade
Other Expense / Income	-20.84	-6.23	-8.19	0.58	-	Upgrade
Pretax Income	-202.49	-172.28	-140.85	-84.55	68.15	Upgrade
Income Tax	2.78	3.79	0	0	0.17	Upgrade
Net Income	-205.28	-176.06	-140.85	-84.55	67.98	Upgrade
Shares Outstanding (Basic)	107	105	104	101	94	Upgrade
Shares Outstanding (Diluted)	107	105	104	101	99	Upgrade
Shares Change	1.26%	1.62%	3.00%	2.14%	17.90%	Upgrade
EPS (Basic)	-1.92	-1.67	-1.36	-0.84	0.72	Upgrade
EPS (Diluted)	-1.92	-1.67	-1.36	-0.84	0.69	Upgrade
Free Cash Flow	-330.63	-188.91	147.75	-107.75	161.03	Upgrade
Free Cash Flow Per Share	-3.10	-1.79	1.42	-1.07	1.72	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	-85.16%	-73.39%	-107.77%	-105.87%	36.25%	Upgrade
Profit Margin	-85.27%	-72.39%	-101.85%	-96.09%	40.27%	Upgrade
Free Cash Flow Margin	-137.34%	-77.67%	106.84%	-122.46%	95.40%	Upgrade
Effective Tax Rate	-	-	-	-	0.26%	Upgrade
EBITDA	-171.67	-161.86	-132.58	-87.8	65.63	Upgrade
EBITDA Margin	-71.31%	-66.54%	-95.87%	-99.78%	38.88%	Upgrade
Depreciation & Amortization	12.49	10.42	8.27	5.94	4.44	Upgrade
EBIT	-184.17	-172.28	-140.85	-93.74	61.19	Upgrade
EBIT Margin	-76.50%	-70.83%	-101.85%	-106.53%	36.25%	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).